Hoddinott Katie, Oblak Michelle L, Wood Geoffrey A, Boston Sarah, Mutsaers Anthony J
Department of Clinical Studies (Hoddinott, Oblak, Mutsaers) and Department of Pathobiology (Wood), Ontario Veterinary College, University of Guelph, Guelph, Ontario N1G 2W1; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida 32610-0126, USA (Boston).
Can J Vet Res. 2019 Jan;83(1):3-10.
Canine osteosarcoma is a devastating disease with an overall poor prognosis. Radiation therapy and bisphosphonates are currently used in combination for palliative treatment, despite a paucity of literature that investigates their combined use. The objectives of this study were to assess the effects of radiation therapy and bisphosphonates on canine osteosarcoma cells when used in combination. Canine osteosarcoma cell lines D17 and Dharma were treated with radiation and pamidronate or zoledronate, both alone and in combination. The effects of these treatments were assessed using clonogenic survival and cell viability assays. Dose-dependent decreases in clonogenic survival and cell viability were observed for both radiation and bisphosphonate treatment. Combination index analysis revealed antagonistic interactions when radiation and bisphosphonates were used in combination at specific doses for both D17 and Dharma osteosarcoma cells. Further investigation of the combined effects of radiation and bisphosphonates for the palliative treatment of canine osteosarcoma is warranted.
犬骨肉瘤是一种预后总体较差的毁灭性疾病。目前，放射治疗和双膦酸盐类药物联合用于姑息治疗，尽管研究它们联合使用的文献较少。本研究的目的是评估放射治疗和双膦酸盐类药物联合使用时对犬骨肉瘤细胞的影响。犬骨肉瘤细胞系D17和Dharma分别接受放射治疗、帕米膦酸盐或唑来膦酸盐治疗，以及两者的联合治疗。使用克隆形成存活和细胞活力测定法评估这些治疗的效果。放射治疗和双膦酸盐治疗均观察到克隆形成存活和细胞活力呈剂量依赖性下降。联合指数分析显示，在特定剂量下，放射治疗和双膦酸盐类药物联合用于D17和Dharma骨肉瘤细胞时存在拮抗相互作用。有必要进一步研究放射治疗和双膦酸盐类药物联合用于犬骨肉瘤姑息治疗的效果。
